| Similar Articles |
|---|
 |
The Motley Fool
March 31, 2008
Brian Lawler |
Corcept's Devotion to Its Lead Drug Corcept Therapeutics will try again with its compound for psychotic depression.   |
The Motley Fool
September 27, 2010
Brian Orelli |
Better Buy: Ariad Pharmaceuticals or Corcept Therapeutics? A battle of drugless companies looking for their first hit. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
The Motley Fool
September 2, 2010
Brian Orelli |
Pfizer Takes an Orphan Into the Fold Pfizer is likely pursuing FoldRx's pipeline and expertise in rare diseases. |
Pharmaceutical Executive
October 1, 2006
Beth Herskovits |
Born Again Mifepristone is best known as an abortion drug. But it appears to be on the verge of a second career - treating a severe form of major depression. |
Pharmaceutical Executive
September 1, 2008
Jeffrey S. Aronin |
The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
December 1, 2009
Brian Orelli |
Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa. |
Wired
October 2006
Thomas Goetz |
The Thin Pill 75 million Americans may have something called metabolic syndrome. How Big Pharma turned obesity into a disease - then invented the drugs to cure it. |
Pharmaceutical Executive
July 30, 2007
Louis A. Morris |
Safety Net The new Culture of Drug Safety means embracing the benefit of no doubt about a product's pluses and its minuses. Pharma must learn how patients and prescribers weigh risks and how to spread the word about the advantages. |
The Motley Fool
February 3, 2010
Brian Orelli |
Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease. |
American Family Physician
September 1, 2000 |
Cushing's Syndrome and Cushing's Disease What is Cushing's syndrome?... What causes Cushing's syndrome?... What is Cushing's disease?... What are the signs and symptoms of Cushing's syndrome and disease?... How does my doctor find out if I have Cushing's syndrome or disease?... How are Cushing's disease and syndrome treated?... |
The Motley Fool
May 28, 2004
Charly Travers |
Don't Be a Biotech Gambler Stand on solid ground by learning to assess the value of future drug programs. Investing in biotechs -- rather than simply speculating in the sector -- requires a solid assessment of how much a company's drug programs could be worth. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
American Family Physician
September 1, 2000 |
Cushing's Disease: Clinical Manifestations and Diagnostic Evaluation The most common endogenous cause of Cushing's syndrome is Cushing's disease. Frequent clinical findings include weight gain, truncal obesity, striae, hypertension, glucose intolerance and infections... |
American Family Physician
September 15, 2001
David S. Smith |
Health Care Management of Adults with Down Syndrome The family physician's holistic approach to patients forms the basis of good health care for adults with Down syndrome... |
American Family Physician
September 15, 2001 |
Health Issues for Adults with Down Syndrome Are regular check-ups a good idea?... How can I help my relative with Down syndrome have a full life?... My older relative is having some new problems. Could it be Alzheimer's disease?... |
